scispace - formally typeset
M

Manica Negahdaripour

Researcher at Shiraz University of Medical Sciences

Publications -  96
Citations -  2636

Manica Negahdaripour is an academic researcher from Shiraz University of Medical Sciences. The author has contributed to research in topics: Medicine & Epitope. The author has an hindex of 21, co-authored 76 publications receiving 1488 citations. Previous affiliations of Manica Negahdaripour include Shiraz University.

Papers
More filters
Journal ArticleDOI

Arginine Deiminase: Current Understanding and Applications.

TL;DR: The intracellular delivery of ADI and combination therapy seem to be the future strategies in the treatment of arginine auxotrophic cancers.
Journal ArticleDOI

Selected application of peptide molecules as pharmaceutical agents and in cosmeceuticals

TL;DR: Peptide synthesis has become accessible, and advances in peptide engineering, sequencing technologies, and structural bioinformatics have resulted in the rational designing of novel peptides which would lead to the more prominent roles of peptides in the mentioned areas.
Journal ArticleDOI

Characterization of biogenic Fe (III)-binding exopolysaccharide nanoparticles produced by Ralstonia sp. SK03

TL;DR: Treatment of hepatocarcinoma cell line (Hep‐G2) with 1–500 µg/mL concentrations of Fe‐EPS nanoparticles caused 40% increase in the cell viability, which indicated that the biosynthesized nanoparticles were nontoxic and biocompatible.
Journal ArticleDOI

In Silico Designing a Candidate Vaccine Against Breast Cancer

TL;DR: Structural and immunological computational results indicated the potential of the designed construct for proper stimulation of cellular and humoral immune responses against BC and the candidate vaccine could be introduced for BC therapy after the efficacy of it was confirmed by in vivo and in vitro immunological assays.
Journal ArticleDOI

Therapeutic Approaches for COVID-19 Based on the Interferon-Mediated Immune Responses

TL;DR: Investigating the most important signaling pathways activated by coronaviruses to better understand the viral pathogenesis and host immune responses found that administration of interferons or interferon-inducing agents in a prophylactic manner or at early stages of the disease, could mimic the effective antiviral responses against SARS-CoV-2 and reduce the disease severity.